| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7378423 | NOVARTIS | Pyrimidine compound and medical use thereof |
May, 2027
(3 years from now) | |
| US8703781 | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
Oct, 2030
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8835443 | NOVARTIS | Pyrimidine compound and medical use thereof |
Jun, 2025
(1 year, 8 months from now) | |
|
US8835443 (Pediatric) | NOVARTIS | Pyrimidine compound and medical use thereof |
Dec, 2025
(2 years from now) | |
|
US7378423 (Pediatric) | NOVARTIS | Pyrimidine compound and medical use thereof |
Nov, 2027
(4 years from now) | |
| US8952018 | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
Oct, 2030
(7 years from now) | |
|
US8952018 (Pediatric) | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
Apr, 2031
(7 years from now) | |
|
US8703781 (Pediatric) | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
Apr, 2031
(7 years from now) | |
| US8580304 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(8 years from now) | |
| US9271941 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(8 years from now) | |
| US9155706 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(8 years from now) | |
| US9399021 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(8 years from now) | |
|
US9155706 (Pediatric) | NOVARTIS | Pharmaceutical composition |
Jul, 2032
(8 years from now) | |
|
US8580304 (Pediatric) | NOVARTIS | Pharmaceutical composition |
Jul, 2032
(8 years from now) | |
|
US9271941 (Pediatric) | NOVARTIS | Pharmaceutical composition |
Jul, 2032
(8 years from now) | |
|
US9399021 (Pediatric) | NOVARTIS | Pharmaceutical composition |
Jul, 2032
(8 years from now) | |
| US10869869 | NOVARTIS | Method of adjuvant cancer treatment |
Aug, 2033
(9 years from now) | |
|
US10869869 (Pediatric) | NOVARTIS | Method of adjuvant cancer treatment |
Mar, 2034
(10 years from now) | |
Mekinist is owned by Novartis.
Mekinist contains Trametinib Dimethyl Sulfoxide.
Mekinist has a total of 18 drug patents out of which 0 drug patents have expired.
Mekinist was authorised for market use on 29 May, 2013.
Mekinist is available in tablet;oral dosage forms.
Mekinist can be used as mekinist is indicated, in combination with dabrafenib, for the treatment of pediatric patients 1 year of age and older with low-grade glioma (lgg) with a braf v600e mutation who require systemic therapy, mekinist is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test, mekinist(r) is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fda-approved test, and involvement of lymph node(s), following complete resection.
The generics of Mekinist are possible to be released after 02 March, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Mar 16, 2030 |
| New Indication (I) | Jun 22, 2025 |
| Pediatric Exclusivity (PED) | Dec 22, 2025 |
Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient
Market Authorisation Date: 29 May, 2013
Treatment: Mekinist is indicated, in combination with dabrafenib, for the treatment of pediatric patients 1 year of age and older with low-grade glioma (lgg) with a braf v600e mutation who require systemic thera...
Dosage: TABLET;ORAL
MEKINIST family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic